Eli Lilly and Company’sLLY shares tumbled 7.8% with the company announcing the termination of the development of its late stage cholesteryl ester transfer protein (CETP) inhibitor, evacetrapib. Lilly’s decision was based on the recommendation of an independent data monitoring
Lilly (LLY) Halts CETP Inhibitor Development, Shares Tumble
